I keep going back the HL financing as an indicator that IF RVX are getting ANY hints via the patient reports of the drug NOT working, in any of the CVD, CKD, or, CD.... that it would be reflected in the financing that HL is always willing to participate in. If HL were to sense anything that would indicate bad news,.. they would, minimum, want the financing to be done at a much lower price.

Also RVX would be pumping the stock, getting alot more financing from whoever, so as to create a buffer of cash to shield them from the price fall when primary endpoint  would not be met,... so as to allow them to at least start a new trial without having to dilute at .20 cents.

They certianly are not ACTING like a company that has indications that the primary endpoint will not be met.